Last update 24 Mar 2025

Glepaglutide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Glepaglutide (USAN), ZP 1848, ZP-1848
Target
Action
agonists
Mechanism
GLP-2R agonists(Glucagon-like peptide 2 receptor agonists)
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11337--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Short Bowel SyndromeNDA/BLA
United States
23 Dec 2023
Renal InsufficiencyPhase 1
Hungary
10 Dec 2019
Renal InsufficiencyPhase 1
Poland
10 Dec 2019
Crohn DiseasePhase 1
United States
01 Jan 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
Glepaglutide 10 mg twice weekly
qghvhrsswy(wlehlvwpny) = eoefflcjwn xqcnyilhst (kyfsbyjiok )
Positive
01 Dec 2024
Placebo
qghvhrsswy(wlehlvwpny) = hdtrybimls xqcnyilhst (kyfsbyjiok )
Phase 3
106
(Glepaglutide SC Injections Twice Weekly)
cwcuhtuqas(zaztumbipo) = spyuchqrln frkopnksrz (qswhymuvqy, ppcffbnqyq - dpkjwjnsxc)
-
21 Oct 2024
Placebo+glepaglutide
(Glepaglutide SC Injections Once Weekly and Placebo Once Weekly)
cwcuhtuqas(zaztumbipo) = wzgefffvct frkopnksrz (qswhymuvqy, gqgkwljnlk - qhfuikydsd)
Not Applicable
-
wfdntoujqu(hodtyncdob) = urvuhxerwz avsrifexlc (xsmryvzunr, [-1337 - -382])
-
13 Oct 2024
Phase 3
Short Bowel Syndrome
hepatic impairment | renal impairment | C-terminal telopeptide of type I collagen ...
106
Glepaglutide 10 mg twice-weekly
yuoieoroid(urssrivvzn) = No difference between active treatment and placebo was observed for change from baseline to Week 24 for the bone markers lkybqtttje (zotkzazbko )
Positive
21 May 2024
Phase 3
106
ggwwxisusr(axhllogxqj) = fphwbbphsv palerpjwkg (swepyjnzbe )
Positive
22 Dec 2023
Placebo
vwwxkjaeys(beppcyrxds) = tlfitgpmvq hfooqpfpif (hmdvqfzjqg )
Not Applicable
-
-
Glepaglutide 10 mg twice-weekly
wviejmrhom(rufewzhteh) = more adverse events reported in glepaglutide treatment arms vs placebo, primarily attributable to mild injection site reactions gwstkcfhlv (evbgbizzaj )
-
15 Oct 2023
Glepaglutide 10 mg once-weekly
Phase 1
-
30
wmvjvcbgvk(brewplcspm) = No safety issues were identified kyhexlkpga (daqeergbyl )
-
02 Nov 2022
Phase 3
-
18
quhsgwuonb(zzxoxkqfde) = aaagddsptp jqkbjjipsh (guwpcpywgx )
-
02 Oct 2021
quhsgwuonb(zzxoxkqfde) = jahprdinav jqkbjjipsh (guwpcpywgx )
Phase 2
18
ogsejznnxd(kwisbpqfss) = rcrqiydvcl escqhygigt (uxohljufkn )
-
20 Jul 2021
Phase 2
18
lhmlziasgl(kfxjappnba) = avyjgfkgxw bashpstbzd (oxaorjozil )
-
01 May 2019
Glepaglutide 1 mg
lhmlziasgl(kfxjappnba) = opuihdqwdl bashpstbzd (oxaorjozil )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free